Citations

Showing 10 of 108094 citations.

CRAN-37. MOLECULAR HETEROGENEITY OF SUBEPENDYMAL GIANT CELL ASTROCYTOMAS IN PATIENTS WITH MILD-PHENOTYPE TUBEROUS SCLEROSIS COMPLEX
Rao, Amulya Nageswara, Nesvick, Cody L. , Rao, Amulya A. Nageswara , Raghunathan, Aditya , Daniels, David J.

Mayo Clinic

Neuro-Oncology | June 21, 2018 | Volume: 20 | Issue: suppl_2 | Pages: i44-i44

10.1093/neuonc/noy059.072 Get It

RADI-17. EVALUATION OF A NOVEL 18F-LABELED TRYPTOPHAN TRACER FOR PET IMAGING OF BRAIN TUMORS IN A MEDULLOBLASTOMA MOUSE MODEL
Dalvi, Nagma , Zhang, Shaohui , Litan, Alisa, Xin, Yangchun , Li, Zhiqin , Li, Hua , Cai, Hancheng, Chugani, Harry T. , Chugani, Diane C. , Yue, Xuyi , Langhans, Sigrid A.

Mayo Clinic

Neuro-Oncology | June 21, 2018 | Volume: 20 | Issue: suppl_2 | Pages: i173-i173

10.1093/neuonc/noy059.657 Get It

IMMU-12. T-CELL THERAPIES DEMONSTRATE EFFICACY WITHOUT TOXICITY IN IMMUNOCOMPETENT MODELS OF BRAINSTEM TUMORS
Schuelke, Matt, Wongthida, Phonphimon , Thompson, Jill , Kottke, Tim , Sánchez-Pérez, Luis, Vile, Richard G. , Schuelke, Matthew , Evgin, Laura , Sampson, John Howard

Mayo Clinic

Neuro-Oncology | June 21, 2018 | Volume: 20 | Issue: suppl_2 | Pages: i101-i101

10.1093/neuonc/noy059.328 Get It

ARNT/HIF‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma
Liu, Yingmin , Yi-cheng, LU , Liu, Xiaobo , Liu, Xuelian , Ye, Long , Sun, Yue , Wang, Xue , Yang, Pei‐Yu , Gao, Sujun , Kumar, Shaji , Jin, Fengyan , Dai, Yun , Li, Wei , Dai, Yun , Wu, Chuan, Yang, Ting , Yang, Yanping , Li, Qingchao , Yu, Xiaoyuan

Mayo Clinic

Cancer Medicine | June 21, 2018 | Volume: 7 | Issue: 8 | Pages: 3899-3911

10.1002/cam4.1596 | PMID 29926531 Get It

Abstract1q21 gain is a common cytogenetic abnormality featuring high‐risk multiple myeloma (HRMM). However, the molecular mechanism underlying the adverse prognostic effect of 1q21 gain remains largely unclear. Here, we report that ARNT/HIF‐1β, a 1q21 gene, is highly expressed in HRMM and induced by microenvironmental hypoxia, which confers drug resistance and correlates with inferior outcome. Analysis of the gene expression profile database revealed that ARNT expression was upregulated in MM and increased with disease progression or in HRMM subtypes (particularly 1q21 gain), while correlated to shorter overall survival. In a cohort of 40 MM patients, qPCR further validated that ARNT expression was higher in MM patients than normal donors. MM cells carrying 1q21 gain or acquired drug resistance displayed a robust increase in HIF‐1β protein level. Hypoxia induced HIF‐1β expression via a NF‐κB‐dependent process. Notably, HIF‐1β overexpression impaired bortezomib sensitivity, whereas shRNA knockdown of ARNT reversed hypoxia‐mediated drug resistance. Together, these findings suggest that ARNT/HIF‐1β might represent a novel biomarker for risk stratification and prognosis of HRMM patients, as well as a potential therapeutic target for overcoming 1q21 gain‐ or microenvironment‐mediated and acquired drug resistance in MM.
Global development and adaptive functioning in children with epilepsy
Kirsch, Alexandra C. , Zaccariello, Michael J.

Mayo Clinic

Developmental Medicine & Child Neurology | June 21, 2018 | Volume: 61 | Issue: 2 | Pages: 110-111

10.1111/dmcn.13941 | PMID 29926470 Get It

This commentary is on the original article by Reilly et al. on pages 145–151 of this issue.
Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis
Kotze, Paulo Gustavo , McKenna, Nicholas P. , Almutairdi, Abdulelah , Kaplan, Gilaad G. , Raffals, Laura E. , Loftus, Edward V. , Mckenna, Nicholas, Loftus, Edward V , Kotze, Paulo G , Kaplan, Gilaad G , Ma, Christopher , Panaccione, Remo , Lightner, Amy L. , McKenna, Nicholas P

Mayo Clinic

Therapeutic Advances in Gastroenterology | June 21, 2018 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/1756284818783614 | PMID 29977340 Get It

Background: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn’s disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-treated patients undergoing nonintestinal operations. Methods: A case-matched study was performed at two inflammatory bowel disease (IBD) referral centers. Adult patients with CD and UC who underwent a nonintestinal surgical procedure during treatment with VDZ were included. Patients who had their last VDZ infusion up to 12 weeks before the procedure were considered exposed and were matched in a 1:1 ratio to patients without VDZ therapy, according to type of surgical procedure, age, and sex. The primary outcome was overall risk of early postoperative infectious complications (up to 30 days after surgery), readmissions, reoperations, surgical site infections, and other infections. The VDZ and control groups were subsequently compared using the Pearson χ2 test and Wilcoxon rank sum. Results: We identified 34 patients treated with VDZ who underwent 36 nonintestinal surgical procedures. These patients were matched with 36 control procedures. Postoperative complications were not different between the VDZ-treated and control cohorts for all outcomes analyzed: infectious complications occurred in 14% versus 8% ( p = 0.45), superficial surgical site infections 6% versus 0% ( p = 0.15), reoperations 6% versus 3% ( p = 0.56) and readmissions 11% versus 6% ( p = 0.37). Conclusions: VDZ-treated patients with IBD undergoing nonintestinal procedures did not have an increased risk of overall postoperative infections or other complications compared with matched controls.
Multigenerational transmission of liability to psychiatric illness in offspring of parents with bipolar disorder
Post, Robert M. , Altshuler, Lori L., Kupka, Ralph , Frye, Mark A. , Grunze, Heinz , Suppes, Trisha, Keck, Paul E., Leverich, Gabriele S., Nolen, Willem A. , Grunze, Heinz , McElroy, Susan L. , Rowe, Michael J.

Mayo Clinic

Bipolar Disorders | June 21, 2018 | Volume: 20 | Issue: 5 | Pages: 432-440

10.1111/bdi.12668 | PMID 29926532 Get It

Introduction Instead of the typical assessment of risk of illness in the offspring based on a parent with bipolar disorder, we explored the potential multigenerational conveyance across several disorders of the vulnerability to illness in the offspring of a patient with bipolar disorder. Methods A total of 968 outpatients (average age 41 years) with bipolar illness gave informed consent and filled out a detailed questionnaire about a family history in their parents, grandparents, and offspring of: depression; bipolar disorder; alcohol abuse; substance abuse; suicide attempt; or “other” illness. Of those with children, 346 were from the USA and 132 were from Europe. Amount and type of illness in progenitors in two and three previous generations were related to offspring illness. Results The type of illness seen in both prior generations was associated with the same type of illness in the offspring of a bipolar patient, including depression, bipolar disorder, alcohol and substance abuse and “other” illness, but not suicide attempts. There was an impact of multiple generations, such that depression in grandparents and/or great‐grandparents increased the risk of depression in the offspring from 12.6% to 41.4%. Conclusions A family history of illness burden in prior generations was previously related to an earlier age of onset of bipolar illness in our adult patients with bipolar disorder and is now also found to be related to the incidence of multiple psychiatric illnesses in their offspring. Genetic and epigenetic mechanisms deserve consideration for this multigenerational conveyance of illness vulnerability, and clinical and public health attempts to prevent or slow this transmission are indicated.
Design and Testing of a Smartphone Application for Real-Time Self-Tracking Diabetes Self-Management Behaviors
Groat, Danielle , Soni, Hiral , Thompson, Bithika , Cook, Curtiss B. , Grando, Adela , Kaufman, David Ross

Mayo Clinic

Applied Clinical Informatics | June 20, 2018 | Volume: 09 | Issue: 02 | Pages: 440-449

10.1055/s-0038-1660438 | PMID 29925098 Get It

Background Type 1 diabetes (T1D) care requires multiple daily self-management behaviors (SMBs). Preliminary studies on SMBs rely mainly on self-reported survey and interview data. There is little information on adult T1D SMBs, along with corresponding compensation techniques (CTs), gathered in real-time. Objective The article aims to use a patient-centered approach to design iDECIDE, a smartphone application that gathers daily diabetes SMBs and CTs related to meal and alcohol intake and exercise in real-time, and contrast patients' actual behaviors against those self-reported with the app. Methods Two usability studies were used to improve iDECIDE's functionality. These were followed by a 30-day pilot test of the redesigned app. A survey designed to capture diabetes SMBs and CTs was administered prior to the 30-day pilot test. Survey results were compared against iDECIDE logs. Results Usability studies revealed that participants desired advanced features for self-tracking meals and alcohol intake. Thirteen participants recorded over 1,200 CTs for carbohydrates during the 30-day study. Participants also recorded 76 alcohol and 166 exercise CTs. Comparisons of survey responses and iDECIDE logs showed mean% (standard deviation) concordance of 77% (25) for SMBs related to meals, where concordance of 100% indicates a perfect match. There was low concordance of 35% (35) and 46% (41) for alcohol and exercise events, respectively. Conclusion The high variability found in SMBs and CTs highlights the need for real-time diabetes self-tracking mechanisms to better understand SMBs and CTs. Future work will use the developed app to collect SMBs and CTs and identify patient-specific diabetes adherence barriers that could be addressed with individualized education interventions.
Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation
Eftekhari, Rahil , Lima, Stacy Grace de, Mihara, Koichiro , Saifeddine, Mahmoud, Noorbakhsh, Farshid , Scarisbrick, Isobel A. , Hollenberg, Morley D. , Liu, Yu

Mayo Clinic

Biological Chemistry | June 20, 2018 | Volume: 399 | Issue: 9 | Pages: 1023-1039

10.1515/hsz-2018-0001 | PMID 29924723 Get It

AbstractWe propose that in the microenvironment of inflammatory tissues, including tumours, extracellular proteinases can modulate cell signalling in part by regulating proteinase-activated receptors (PARs). We have been exploring this mechanism in a variety of inflammation and tumour-related settings that include tumour-derived cultured cells from prostate and bladder cancer, as well as immune inflammatory cells that are involved in the pathology of inflammatory diseases including multiple sclerosis. Our work showed that proteinase signalling via the PARs affects prostate and bladder cancer-derived tumour cell behaviour and can regulate calcium signalling in human T-cell and macrophage-related inflammatory cells as well as in murine splenocytes. Further, we found that the tumour-derived prostate cancer cells and immune-related cells (Jurkat, THP1, mouse splenocytes) can produce PAR-regulating proteinases (including kallikreins: kallikrein-related peptidases), that can control tissue function by both a paracrine and autocrine mechanism. We suggest that this PAR-driven signalling process involving secreted microenvironment proteinases can play a key role in cancer and inflammatory diseases including multiple sclerosis.
Neurological outcomes by mode of delivery for fetuses with open neural tube defects: a systematic review and meta‐analysis
Tolcher, MC, Shazly, SA, Shamshirsaz, AA, Whitehead, WE, Espinoza, Jimmy , Vidaeff, AC, Belfort, MA, Nassr, AA, Espinoza, J , Nassr, Ahmed A.

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | June 20, 2018 | Volume: 126 | Issue: 3 | Pages: 322-327

10.1111/1471-0528.15342 | PMID 29924919 Get It

BackgroundControversy exists regarding the optimal mode of delivery for fetuses with open neural tube defects.ObjectiveTo compare neurological outcomes among infants with open neural tube defects who underwent vaginal compared with caesarean delivery.Search strategyElectronic databasesMEDLINE,EMBASE, Scopus, and Clinicaltrials.gov were searched from inception to November 2017.Selection criteriaEligible studies included observational or randomised studies comparing vaginal and caesarean delivery in pregnancies with fetal open neural tube defects who did not undergo prenatal repair.Data collection and analysisTwo reviewers independently reviewed abstracts and full‐text articles. Outcomes were compared between vaginal and caesarean delivery and prelabour caesarean versus exposure to labour. The primary outcome was motor–anatomic level difference. Secondary outcomes included shunt requirement, sac disruption, meningitis, and ambulation at 2 years. Meta‐analysis was performed and mean difference or odds ratios with 95% CI were calculated.Main resultsOf 201 abstracts identified in the primary search, nine studies (672 women) met the eligibility criteria. Comparing vaginal and caesarean delivery, there was no significant difference in motor–anatomic level difference (mean difference –0.10, 95%CI−0.58 to 0.38;I2 = 57%). The vaginal delivery group was less likely to require a shunt or have sac disruption [odds ratio (OR) 0.37, 95%CI0.14–0.95 andOR0.46, 95%CI0.23–0.90, respectively]. Comparisons by prelabour caesarean versus exposure to labour showed no significant difference in motor–anatomic level difference (OR1.29, 95%CI0.63–3.21) or ambulation at 2 years (OR2.13, 95%CI0.35–13.12).ConclusionCaesarean delivery was not associated with improved neurological outcomes among fetuses with open neural tube defects.Tweetable abstractAvailable evidence does not support routine caesarean delivery for fetuses with open neural tube defects.